Phio PharmaceuticalsPHIO
13F holders, Q4 2025 (December 31)17holders +6
8new positions
2sold out
$1.05avg. 13F price*
At the end of Q4 2025, 17 institutions reported holding Phio Pharmaceuticals Corp. (PHIO) in their 13F filings, up 6 from Q3 2025. 8 opened new positions and 2 sold out. The largest holders were Geode Capital Management, LLC ($97K), Vanguard Group Inc. ($92K) and Cetera Investment Advisers ($45K).
- Company
- Phio Pharmaceuticals Corp.
- CUSIP
- 71880W501
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $130K |
| Exits | 2 | $2K |
All 13F filers, Q3 2025 → Q4 2025: 176,181 shares bought and 819 shares sold, net +175,362 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Geode Capital Management, LLC | 0.00% | Add +60.0% | 92,638 | $97K |
| Vanguard Group Inc. | 0.00% | No change | 87,628 | $92K |
| Cetera Investment Advisers | 0.00% | Add +26.9% | 42,500 | $45K |
| Northern Trust Corp. | 0.00% | New | 23,758 | $25K |
| DRW Securities, LLC | 0.00% | New | 22,636 | $24K |
| Susquehanna International Group, LLP | 0.00% | New | 20,091 | $21K |
| Two Sigma Investments, LP | 0.00% | New | 14,494 | $15K |
| StoneX Group Inc. | 0.00% | New | 11,828 | $12K |
| Robertson Stephens Wealth Management, LLC | 0.00% | New | 10,800 | $11K |
| Virtu Financial LLC | 0.00% | New | 10,214 | $11K |
| Captrust Financial Advisors | 0.00% | New | 10,000 | $11K |
| UBS Group AG | 0.00% | Add +66007.7% | 8,594 | $9K |
| Morgan Stanley | 0.00% | No change | 6,000 | $6K |
| Bank of America Corp. | 0.00% | Add +0.9% | 1,413 | $1K |
| SBI Securities Co., Ltd. | 0.00% | Add +3.1% | 1,135 | $1K |
| Assetmark, Inc. | 0.00% | No change | 110 | $116 |
| Activest Wealth Management | 0.00% | No change | 9 | $9 |
"% of holder's portfolio" is PHIO's weight in each manager's 13F, not the share of Phio Pharmaceuticals Corp. the manager owns.